It is the cache of It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

Therapeutic vaccines for malignant brain tumors
skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site


Therapeutic vaccines for malignant brain tumors


(6767) Total Article Views

Authors: Michael P Gustafson, Keith L Knutson, Allan B Dietz

Published Date December 2008 Volume 2008:2(4) Pages 753 - 761

Michael P Gustafson1, Keith L Knutson2, Allan B Dietz1

1Division of Transfusion Medicine; 2Department of Immunology, Mayo Clinic, Rochester, MN, USA

Abstract: Malignant gliomas are the most common and aggressive form of brain tumors. Current therapy consists of surgical resection, followed by radiation therapy and concomitant chemotherapy. Despite these treatments, the prognosis for patients is poor. As such, investigative therapies including tumor vaccines have targeted this devastating condition. Recent clinical trials involving immunotherapy, specifically dendritic cell (DC) based vaccines, have shown promising results. Overall, these vaccines are well tolerated with few documented side effects. In many patients receiving vaccines, tumor progression was delayed and the median overall survival of these patients was prolonged. Despite these encouraging results, several factors have limited the efficacy of DC vaccines. Here we discuss the potential of DC vaccines as adjuvant therapy and current obstacles of generating highly pure and potent DC vaccines in the context of malignant glioma. Taken together, the results from earlier clinical studies justify additional clinical trials aimed at improving the efficacy of DC vaccines.

Keywords: malignant glioma, glioblastoma multiforme, vaccine, immunotherapy, dendritic cells

Post to:
Cannotea Citeulike Facebook LinkedIn Twitter

Readers of this article also read:

  • Testimonials

    "I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University.

  • Journal Indexing

    See where all the Dove Press journals are indexed.